CA3255686A1 — Mirdametinib treatment
Assigned to SpringWorks Therapeutics Inc · Expires 2023-09-21 · 3y expired
What this patent protects
The present disclosure relates to amethod for treatingcertaintypcsof tumorsorcancers, suchasplcxifonnneurofibromas (PN). plcxifonn neurofibromas associated with neurofibromatosis ty pe I (NFI-PN). by orally administering an effective amount of mirdametinib to the patient, where a…
USPTO Abstract
The present disclosure relates to amethod for treatingcertaintypcsof tumorsorcancers, suchasplcxifonnneurofibromas (PN). plcxifonn neurofibromas associated with neurofibromatosis ty pe I (NFI-PN). by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on tlic first day of treatment to provide (i) an AUCu-uu less than 400 ng li/mL. (ii) a Cmax no more than 40 ng/mL. or (iii) both.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.